These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20708609)

  • 21. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 22. [Diagnostic value of complexed prostate-specific antigen for prostate cancer].
    Su HW; Li Y; Xu P
    Zhonghua Nan Ke Xue; 2003 Sep; 9(6):431-3. PubMed ID: 14574807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
    Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW; Liu G; Sheng BW
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prostate specific antigen and NF-kB in prostatic disease: relation with malignancy].
    Cansino JR; Vera R; Rodríguez de Bethencourt F; Bouraoui Y; Rodríguez G; Prieto A; de la Peña J; Paniagua R; Royuela M
    Actas Urol Esp; 2011 Jan; 35(1):16-21. PubMed ID: 21256390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crystal structure of human prostate-specific antigen in a sandwich antibody complex.
    Stura EA; Muller BH; Bossus M; Michel S; Jolivet-Reynaud C; Ducancel F
    J Mol Biol; 2011 Dec; 414(4):530-44. PubMed ID: 22037582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.
    Barrabés S; Llop E; Ferrer-Batallé M; Ramírez M; Aleixandre RN; Perry AS; de Llorens R; Peracaula R
    Clin Chim Acta; 2017 Jul; 470():97-102. PubMed ID: 28495148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycosylation of prostate specific antigen and its potential diagnostic applications.
    Vermassen T; Speeckaert MM; Lumen N; Rottey S; Delanghe JR
    Clin Chim Acta; 2012 Oct; 413(19-20):1500-5. PubMed ID: 22722018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
    Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
    Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An In-Depth Glycosylation Assay for Urinary Prostate-Specific Antigen.
    Kammeijer GSM; Nouta J; de la Rosette JJMCH; de Reijke TM; Wuhrer M
    Anal Chem; 2018 Apr; 90(7):4414-4421. PubMed ID: 29502397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection.
    Kekki H; Peltola M; van Vliet S; Bangma C; van Kooyk Y; Pettersson K
    Clin Biochem; 2017 Jan; 50(1-2):54-61. PubMed ID: 27818346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lectin and serum-PSA interaction as a screening test for prostate cancer.
    Basu PS; Majhi R; Batabyal SK
    Clin Biochem; 2003 Jul; 36(5):373-6. PubMed ID: 12849869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer.
    Batabyal SK; Majhi R; Basu PS
    Neoplasma; 2009; 56(1):68-71. PubMed ID: 19152248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.